INTRODUCTION

As life expectancy increases in U.S., healthcare spending is highly concentrated among the highest spenders (1). The top 5% of spenders account for almost half of all healthcare spending, with most costs resulting from hospital care in the last year of life (2). It is unclear whether more intensive and expensive care at the end-of-life (EOL) can be linked to better outcomes (3–5). As acuity scores and ventilator utilization increase across U.S. intensive care units (ICUs) over the past 5 years (6), there have been growing concerns about quality of life (QOL), particularly for patients with chronic lung disease (7). COPD is currently the third leading cause of death in the U.S (8). Patients with end-stage COPD have
comparable or higher symptom burdens (i.e., shortness of breath, fatigue, pain, depression, and anxiety) (6,9–11) and poor QOL (11,12) compared to patients with any other advanced chronic illness.

Palliative care is well-recognized as an optimal comprehensive approach for critically ill patients, particularly during EOL (12–14). It has been shown that a hospital-based palliative care service leads to positive patient satisfaction, fewer hospital admissions and in-hospital deaths, less invasive EOL treatments, or fewer hospital expenditures, all of which in turn promote quality of life (13–19). The physical and psychological needs of COPD patients during EOL are equivalent or exceed those experienced by patients with other chronic illnesses (8,20–22). Nevertheless, palliative care for COPD patients has received relatively little attention (23–26). When compared with patients with cancer or other severe chronic diseases, end-stage COPD patients were less likely to be referred for a palliative consultation (16). COPD patients are more likely than patients with other chronic illnesses to receive a disproportionate amount of life-sustaining treatment (LST) including intensive procedures (8,27) and ICU admissions (28).

Previous studies of patients with chronic illnesses (8,28,29) provide valuable information regarding site of death, intensive care admissions, and use of LSTs. There has also been an increase in the use of palliative care programs for major diagnoses in U.S. hospitals (30). Rush et al. (16) noted palliative care utilization increased 4.5-fold between 2006 and 2012 in patients with end-stage COPD and home oxygen use. Nevertheless, little is known about the temporal changes of LSTs and palliative care services, and their effects on hospital cost, particularly among dying patients with COPD. Using a nationally representative database, we examine 10-year trends of LSTs in U.S hospitals such as systemic procedures, local procedures, surgeries and palliative care utilization in dying COPD patients.

METHODS

1. Data source

This study is a serial, cross-sectional data analysis. We met all of the requirements without explicitly stating the Strength-
3. Variables of interest

The main outcomes were the proportion of patients with LSTs (systemic procedures, local procedures, surgeries), and palliative care by year. Systemic procedures were defined as eight groups: 1) intubation, 2) mechanical ventilation (MV), 3) non-invasive ventilation (NIV), 4) vasopressor use, intravascular pressure measurement, 5) enteral, parenteral infusion of concentrated nutrition, 6) cardiopulmonary resuscitation (CPR), 7) blood transfusion, or 8) hemodialysis. Local procedures were those relevant to COPD patients including thoracentesis or any type of bronchoscopy. Surgeries were relevant to COPD patients including those involving larynx, pharynx, trachea, bronchus, lung, chest wall, or pleura. We calculated the total cost of each hospitalization provided by HCUP by applying hospital-specific and group-average all-payer in-patient cost-to-charge ratios from the Centers for Medicare and Medicaid Services (CMS) to the reported hospital charges. Hospital costs were then adjusted for the annual inflation rate using CMS estimates and were expressed as annual means with 95% confidence intervals (CIs) in 2014 U.S. dollars (35).

Table 1. ICD-9-CM Codes used for Main Disease, Systemic Procedures, Local Procedure, Surgeries, and Palliative Care.

<table>
<thead>
<tr>
<th>Diagnostic categories</th>
<th>ICD-9-CM codes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Principal diagnosis</strong></td>
<td>COPD 491.0, 491.1, 491.20, 491.21, 491.22, 491.8, 491.9, 493.2, 492.0, 492.8, 494.0, 494.1, 496, 506.4</td>
</tr>
<tr>
<td><strong>Systemic procedures</strong></td>
<td>Intubation 96.01, 96.02, 96.03, 96.04, 96.05</td>
</tr>
<tr>
<td>Mechanical ventilation 96.70, 96.71, 96.72</td>
<td></td>
</tr>
<tr>
<td>Non-invasive ventilation 93.90</td>
<td></td>
</tr>
<tr>
<td>Infusion of vasopressor or intravascular pressure measurement 0017, 0067, 0068, 0069</td>
<td></td>
</tr>
<tr>
<td>Enteral or parenteral infusion of concentrated nutrition 99.60, 99.15</td>
<td></td>
</tr>
<tr>
<td>Cardiopulmonary resuscitation 99.60</td>
<td></td>
</tr>
<tr>
<td>Blood transfusion 99.00, 99.01, 99.02, 99.04, 99.05, 99.06, 99.07, 99.08, 99.09</td>
<td></td>
</tr>
<tr>
<td>Hemodialysis 39.95, V45.11, V56.0</td>
<td></td>
</tr>
<tr>
<td><strong>Local procedures</strong></td>
<td>Thoracentesis or bronchoscopies 32.01, 32.24, 32.28, 33.21, 33.22, 33.23, 33.24, 33.26, 33.27, 33.71, 33.72, 33.73, 33.78, 34.91, 34.92</td>
</tr>
<tr>
<td>Bronchus, lung 32.09, 32.10, 32.20, 32.21, 32.23, 32.25, 32.26, 32.27, 32.29, 32.30, 32.39, 32.41, 32.49, 32.50, 32.59, 33.00, 33.10, 33.20, 33.21, 33.28, 33.29, 33.31, 33.32, 33.33, 33.34, 33.39, 33.41, 33.42, 33.43, 33.48, 33.49, 33.50, 33.51, 33.52, 33.53, 33.54, 33.55, 33.56, 33.57, 33.58, 33.59, 33.60, 33.91, 33.92, 33.93, 33.99</td>
<td></td>
</tr>
<tr>
<td>Chest wall, pleura 34.01, 34.02, 34.03, 34.04, 34.05, 34.06, 34.09, 34.10, 34.20, 34.21, 34.22, 34.23, 34.24, 34.26, 34.28, 34.29, 34.30, 34.40, 34.51, 34.52, 34.59, 34.60, 34.71, 34.72, 34.73</td>
<td></td>
</tr>
<tr>
<td><strong>Palliative care</strong></td>
<td>V66.7</td>
</tr>
</tbody>
</table>

4. Statistical analysis

First, the CAGR was used to quantify temporal trends of LSTs and palliative care and its statistical significance was tested by Rao-Scott correction for $x^2$ tests for categorical variables. CAGR supposes that year A is x and year B is y, $CAGR = (y/x)^{(1/(B-A))-1}$ and has been widely used for health care valuation (36,37). Pearson $x^2$ test for temporal trends in clustered binary data (yes/no) was limited for testing homogeneity in a population with a skewed distribution (38). Hierarchical modeling analysis was applied to adjust for multi–levels of patient and hospitals as suggested by the HCUP when analyzing the NIS dataset (39). Because the distribution of hospital cost was skewed, log–transformation was applied to a regression model. Multilevel and multivariate regression analysis of hospital cost was performed to determine the effects of patients, hospital factors, LSTs (systemic procedures, local procedures, surgeries), and palliative care on hospital cost. Based on the results from regression analyses, further exploratory analyses were conducted examining the statistical difference of illness severity 1) between systematic procedures and palliative care, and 2) between private insurance and Medicaid. Also, the statistical difference of LSTs and palliative care between private insurance and Medicaid was tested using the Rao–Scott correction of $x^2$ test. To evaluate the impact of missing data, we compared baseline characteristics. We multiply imputed missing hospital cost using regression analysis models. There were no statistical differences among baseline characteristics between analyzed and missing data. The model was determined to be stable and the assumption of randomly missing data was found to be reasonable using the observed data. All analyses were performed using SAS statistical software version 9.4 (SAS Institute Inc., Cary, NC). All reported P–values were 2–tailed and P–value <0.05 was considered statistically significant.

RESULTS

1. Descriptive statistics

From 2005 to 2014, the NIS database contained 77,394,755 hospital inpatient stays: 7,221,164 terminal hospitalizations with age ≥18 years: 102,192 patients with main diagnosis of COPD: final analysis included 79,314 patients as shown in Figure 1. Table 2 presents a descriptive analysis of patient and hospital characteristics. More than half of patients received systemic procedures (52.05%), while less than one in ten patients received local procedures (7.87%) or surgeries (3.68%); 29.95% received palliative care.

2. Temporal trends statistics

Figure 2 presents the CAGRs of LSTs and palliative care. The CAGRs of systemic procedures, local procedures, surgeries,
and palliative care were 5.98%, 3.54%, 3.49%, and 19.89%. Systemic procedures and palliative care increased over time (both P<0.001), but the proportions of local procedures and surgeries were unchanged over time.

Figure 3 presents the CAGRs of each kind of systemic procedure. The CAGRs of intubation, MV, NIV, CPR, and hemodialysis were 4.32%, 4.51%, 4.69%, 3.82%, 3.32%, and these items increased over time (all P<0.05). However, the CAGRs of enteral/parenteral infusion of concentrated nutrition and blood transfusion were −3.16% and −5.07% and these items decreased over time (P=0.020; P<0.001, respectively). Vaso-

pressor use/intravascular monitoring was unchanged.

Figure 4 presents annual mean and 95% CI of hospital cost. The hospital cost increased over time (P<0.001) and the CAGR was 5.81%.

3. Log-transformed multivariate regression analysis of hospital cost

Table 3 presents log-transformed multi-level multivariate regression analysis of hospital cost. Each year increased hospital cost by 0.0581 (P<0.001) that can be interpreted as a CAGR of 5.81%. Black patients (estimate=0.069; P=0.029) and other non-Hispanic patients (estimate=0.072; P=0.011) were associated with increased hospital cost compared to white counterparts. Higher APR–DRG patients were associated with increased hospital cost. Compared with private insurance patients, Medicare (estimate=0.480; P<0.001) and Medicaid (estimate=0.461; P<0.001) patients were associated with increased hospital cost. Higher income patients were associated with increased hospital cost. A small hospital was associated with increased hospital cost (estimate=0.064; P=0.003). Systemic procedures (estimate=0.590; P<0.001), local procedures (estimate=0.720; P<0.001), or surgeries (estimate=0.552; P<0.001) were associated with increased hospital cost. Palliative care was associated with decreased hospital cost (estimate=−0.287; P<0.001).

4. Exploratory analyses

Figures 5 and 6 present statistically significant differences (P<
0.001) of APR–DRG illness severity between systemic procedures and palliative care (Figure 5) and between private insurance and Medicaid (Figure 6). Higher APR–DRG patients were more likely to receive systemic procedures rather than palliative care; Medicaid patients were more likely to have higher APR–DRG compared to private insurance patients. Figure 7 presents health service utilization differences between private insurance and Medicaid patients. Medicaid patients were more likely to receive LSTs (all systemic procedures, local procedures, and surgeries; all P<0.001) and were less likely to receive palliative care compared to their private insurance counterparts (P<0.001).

### DISCUSSION

To the best of our knowledge, the current study reports the first ten–year national temporal trends of LSTs, palliative care,
and their effects on hospital cost in dying COPD patients in U.S. hospitals. The major temporal trends were increased systemic procedures and palliative care, without change in local procedures and surgeries. Teno et al. (29) found that ICU care increased from 2000 to 2009, with 29.2% of decedents in 2009 experiencing an ICU care in the last months of life. In our analysis, respiratory tract supporting systemic procedures such as intubation, MV, or NIV, were the most common procedures, which might be linked with the national increase in MV and NIV ICU utilization reported by Lilly et al. (7) and other nationally representative findings from Tschirhart et al. (5). Perhaps a late referral for hospital-based palliative consultation or hospice referral resulted in initiation of LST until the goal of care is firmly established by the patient or by healthcare proxy. This dilemma is particularly challenging for non-cancer patients. Unlike typical cancer patients whose prognosis is predictable, the disease trajectories for chronic advanced non-cancer disease, such as COPD, are heterogeneous which makes it difficult to accurately assess prognosis (23,27,34,40) and introduce palliative care appropriately. In contrast, other systemic procedures such as blood transfusion and nutrition decreased over time. These findings are consistent with recent reports identifying that restrictive red cell transfusion is not inferior to liberal transfusion except for heart disease (41) and that percutaneous gastrostomy tube feeding might not improve survival or aspiration pneumonia risks when compared to conservative approaches such as nasogastric tube feeding (42).

Compared to the previous reports on patients with advanced COPD by Rush et al. (16) (1.7%), the magnitude of palliative care utilization in our study indicates it is much more common (29.95%). Current hospital-based palliative care programs alone may not be sufficient to affect critical illness care utilization such as length of stay and reciprocal hospice care enrollment among critically ill patients requiring hospital inpatient care (43). In addition, Yaqoob et al. (44) reported that national hospice care in patients dying with COPD has been increasing from 2.2% in 2006 to 9.3% in 2015, but, is still under-utilized. Palliative care’s impact on healthcare utilization such as ICU care and medical procedures can be largely and more directly linked with cancer patients as compared to non-cancer patients (15,18). Data collection limited to dying patients and more recent years (2013 and 2014) might explain the increase in palliative care utilization.

The more interesting finding is the increased pattern of palliative care utilization with a “level and slope change” (45). A pattern of exponential increase started from 2008 and persisted until 2011. There is a plateau from 2012 until 2014. The efforts of healthcare professional societies such as the American College of Chest Physicians (ACCP) to promote EOL communication and advance care planning (ACP) was brought to fruition in dying COPD patients (46,47). The momentum of another “level and slope change” in palliative care is expected around 2016 when the CMS began to allow healthcare providers to bill for ACP discussion time using two new Current Procedural Terminology (CPT) codes, 99497 and 99498 from January 2016 (48).

Hospital cost increases over time in our analysis. We apply higher inflation rate using the CMS’ measurement of hospital care compared to the inflation rate using the Consumer Price Index (CPI) for medical care available from the U.S. Bureau of Labor Statistics (49). We observe the cost-saving effect of palliative care as seen in previous cost analysis studies (15,18,50), but we add the findings of a cost-increase effect of LSTs. The magnitude of cost-increases from LSTs (systematic procedures 59.0%; local procedures 72.0%; surgeries 55.2%) exceeded the cost-saving effect of palliative care (~28.7%); therefore, annual hospital cost increased by 5.81% in our study.

We find health insurance effects on different health outcomes. Medicaid patients are sicker than private insurance patients. There is a disparity of LSTs and palliative care utilization between private insurance and Medicaid patients. Medicaid patients receive more LSTs and less palliative care compared to private insurance patients. We speculate that Medicaid COPD patients not only receive less preventive care before hospital admission but also discuss ACP less frequently compared to private insurance patients.

We acknowledge several limitations. We relied on ICD–9–CM codes that may have limited accuracy in capturing procedures and palliative care due to incorrect or missing data. Second, we could not capture stage or pharmacologic treatment of COPD before and during hospital care. Third, the NIS dataset could link the purpose of local procedures or surgeries, palliative vs. life-sustaining, suggesting that these procedures or surgeries might have been performed for both or either pal-
한계가 있는 목적이 산업적 또는 생명수호 목적이 있다. 전체 대규모 데이터와 10년 연구 기간을 고려하여 임상적인 추세는 우리 연구의 가장 큰 운동으로 인한 비용 증가와 palliative care 이용율 증가의 영향을 미치고 있다. 우리는 largely datasets의 가장 큰 경제적 영향을 미치며, 3894명의 환자가 최종 분석에 사용되었다. 병원 의료비는 연평균 성장률이 5.83% (P<0.001)였으며, 전산지치치료와 환경의료의 연평균성장률은 각각 5.98%와 19.89%였다. (모두, P<0.001). 전산지치치료, 호흡기 치료, 호흡기 수술은 각각 59.04%, 72.00%, 55.26%의 병원 의료비 상승에 영향을 주었다 (모두, P<0.001). 전산지치치료는 28.71%의 병원 의료비 감소에 영향을 주었다 (P<0.001).

결론: 미국에서 만성폐쇄성폐질환으로 사망하는 환자 중 전산지치치료는 병원 의료비 상승의 주된 원인인 반면 완화의료 이용은 비용 절감에 영향이 있는 것으로 파악되었다.

중심단어: 만성폐쇄성폐질환, 의료비 및 의료비 분석, 보건정책, 완화의료, 단절적 시계열 분석

REFERENCES


